Statins as an Adjuvant Therapy for Psychotic Disorders: Current Evidence with a Systematic Overview of Double-Blind Placebo Controlled Trials
| Autor: | Maya J. L. Schutte, Erna van ‘t Hag, Iris E. C. Sommer, Lyliana G Nasib, Marc M. Bohlken, Tjardo S Postma, Peter Martens, Marieke J. H. Begemann, Selene R. T. Veerman |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
medicine.medical_specialty Cholesterol business.industry Inflammation medicine.disease_cause Placebo medicine.disease behavioral disciplines and activities Pathophysiology Double blind chemistry.chemical_compound chemistry Schizophrenia Internal medicine mental disorders medicine Adjuvant therapy medicine.symptom business Oxidative stress |
| Zdroj: | Journal of Brain Disorders. 1 |
| ISSN: | 2578-6571 |
| DOI: | 10.36959/524/325 |
| Popis: | Evidence is accumulating that inflammatory processes play a role in the pathophysiology of schizophrenia. This suggests that anti-inflammatory drugs might have beneficial effects in the treatment of schizophrenia patients. Statins have cholesterol independent effects on inflammation and oxidative stress and could potentially improve positive, negative and/or cognitive symptoms of schizophrenia. We provide an overview of the literature regarding the effects of statins in the treatment of schizophrenia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|